We are singularly focused on advancing aldoxorubicin by supplying the capital and operational expertise needed to bring it to patients sooner.
Learn about Aldox
At the end of 2022, Sid Sijbrandij was diagnosed with osteosarcoma and was treated with doxorubicin, nicknamed “the red devil” for its vivid color and punishing side effects.
Sid experienced both the power of doxorubicin and its brutal limits, including the cardiac toxicity that constrains how much meaningful treatment exposure patients are able to receive.
When Sid learned about aldoxorubicin, a tumor-targeted anthracycline, he saw the possibility of a better way to deliver a drug as important as doxorubicin.
Determined to help advance that possibility for future patients, Sid helped launch Gemini Therapeutics.